Novartis AG (NVS) - Wutah bathi EPS kuartalan

Novartis AG stability across various jurisdictions shields it from geopolitical risks, as confirmed by the quarterly EPS comparison on the GURU.Markets base chart, where the -69.10 mark reflects the current state. Business efficiency relies on powerful research centers in the EU and US, while the implementation of AI in digital biology accelerates the release of new therapeutic agents.

Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan novartis.com (NVS): kanggo periode 04.07.2022 - 15.11.2026

Rincian metrik komprehensif lan analitis novartis.com (NVS)

- rega saham lan prakiraan rega para ahli:

Rega saham Novartis AG|NVS - Prakiraan gabungan firma investasi

- indikator kapitalisasi pasar:

Kapitalisasi pasar Novartis Corporation|NVS - Rega Tumbas Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham Novartis|NVS - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku novartis.com|NVS - Aset Neraca Perusahaan

- data tingkat utang lan likuiditas finansial:

- rincian bathi lan kelipatan pasar:

NVS - Bathi pungkasan|Bathi mangsa ngarep Novartis AG|NVS - Rasio rega pasar marang bathi resik|Pangali Forward P/E novartis.com|NVS - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Novartis Corporation|NVS - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Novartis|NVS - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan novartis.com|NVS - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Novartis AG

- statistik dodolan lan pendapatan perusahaan:

NVS - Total volume dodolan perusahaan|Prakiraan pendapatan perusahaan Novartis AG|NVS - Rasio kapitalisasi marang pendapatan|Multiplikator forward rega marang pendapatan Novartis

Analisis komprehensif perusahaan:Novartis Inc., NVS

For the long-term investor, Novartis AG represents an asset with high potential for fundamental stability. Quarterly EPS growth measures the percentage change in net profit per share compared to the same period last year. By analyzing the current quarterly EPS growth rate, one can assess the effectiveness of the commercialization of innovative drugs for oncology and cardiology therapies. This indicator reflects the actual conversion of R&D successes into shareholder value. The stability of this metric confirms the viability of the company's business model.

Pesaing langsung